Latest Health News
Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94%…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma…
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
September 19, 2025 16:18 ET | Source: MBX Biosciences, Inc. CARMEL, Ind.,…
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future…
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the…
